ImmunoGen, Inc., a clinical-stage biotechnology company, focuses on developing antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm, as well as coltuximab ravtansine, a CD19-targeting ADC, which is in Phase II trial for DLBCL. ImmunoGen, Inc. has collaborations with Roche; Bayer HealthCare AG; Sanofi; Biotest AG; Novartis Institutes for BioMedical Research, Inc.; Eli Lilly and Company; Amgen; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Jazz Pharmaceuticals plc; and Debiopharm International SA. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone781-895-0600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$53.82 million
Profitability
Miscellaneous
Employees293
Next Earnings Date5/3/2019 (Estimated)
OptionableOptionable
ImmunoGen (NASDAQ:IMGN) Frequently Asked Questions
What is ImmunoGen's stock symbol?
ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."
How were ImmunoGen's earnings last quarter?
ImmunoGen, Inc. (NASDAQ:IMGN) released its quarterly earnings results on Friday, February, 8th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.33) by $0.06. The biotechnology company had revenue of $13.79 million for the quarter, compared to analysts' expectations of $12.42 million. ImmunoGen had a negative net margin of 311.94% and a negative return on equity of 499.19%. The firm's revenue for the quarter was down 65.0% compared to the same quarter last year. During the same period last year, the company earned ($0.11) EPS. View ImmunoGen's Earnings History.
When is ImmunoGen's next earnings date?
What guidance has ImmunoGen issued on next quarter's earnings?
ImmunoGen issued an update on its FY 2019 earnings guidance on Friday, February, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $40-45 million, compared to the consensus revenue estimate of $64.43 million.
What price target have analysts set for IMGN?
9 brokers have issued 1-year price targets for ImmunoGen's stock. Their forecasts range from $5.00 to $20.00. On average, they expect ImmunoGen's share price to reach $14.60 in the next twelve months. This suggests a possible upside of 154.8% from the stock's current price. View Analyst Price Targets for ImmunoGen.
What is the consensus analysts' recommendation for ImmunoGen?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ImmunoGen.
What are Wall Street analysts saying about ImmunoGen stock?
Here are some recent quotes from research analysts about ImmunoGen stock:
- 1. HC Wainwright analysts commented, "Our 12-month, $18 price target on shares of ImmunoGen is based on a 13-year DCF-driven, sum-of-the-parts analysis. Our DCF analysis is based on: beta of 1.8, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 12.0%, and tax rate of 12% beginning in FY 2028. Note, our $18 price target is leveraged on the outcome of the mirvetuximab soravtansine’s Phase 3 FORWARD I study, which represents approximately 89% of our target (risk-adjusted NPV of $16 per share). Key risks to our valuation include: emergence of ADC-related safety concerns, clinical, regulatory, and financials risks. ImmunoGen, Inc." (1/3/2019)
- 2. According to Zacks Investment Research, "ImmunoGen has made significant progress with regard to its lead ovarian cancer candidate, mirvetuximab soravtansine. Successful development and subsequent approval of the candidate will be a huge boost to the company as the ovarian cancer market has immense potential. The company has collaborations with big healthcare companies which not only validate its technology but also provides it with funds in the form of milestone and royalty payments. However, ImmunoGen is heavily dependent on its lead candidate, mirvetuximab soravtansine. Hence, any kind of development or a regulatory setback could hamper the stock. The ovarian cancer space being competitive is also a matter of concern for the company. The company’s shares have outperformed the industry so far this year." (9/24/2018)
Has ImmunoGen been receiving favorable news coverage?
Media headlines about IMGN stock have been trending somewhat positive on Saturday, according to InfoTrie Sentiment. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. ImmunoGen earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term.
Are investors shorting ImmunoGen?
ImmunoGen saw a drop in short interest in the month of January. As of January 31st, there was short interest totalling 14,513,485 shares, a drop of 10.7% from the January 15th total of 16,243,883 shares. Based on an average daily trading volume, of 2,187,592 shares, the short-interest ratio is currently 6.6 days. Approximately 9.9% of the shares of the stock are sold short. View ImmunoGen's Current Options Chain.
Who are some of ImmunoGen's key competitors?
Some companies that are related to ImmunoGen include HUTCHISON CHINA/S (HCM), Agios Pharmaceuticals (AGIO), Emergent Biosolutions (EBS), Blueprint Medicines (BPMC), Ascendis Pharma A/S (ASND), Ultragenyx Pharmaceutical (RARE), ACADIA Pharmaceuticals (ACAD), Intercept Pharmaceuticals (ICPT), Global Blood Therapeutics (GBT), Mirati Therapeutics (MRTX), Reata Pharmaceuticals (RETA), Ligand Pharmaceuticals (LGND), Arena Pharmaceuticals (ARNA), Endo International (ENDP) and Akcea Therapeutics (AKCA).
What other stocks do shareholders of ImmunoGen own?
Who are ImmunoGen's key executives?
ImmunoGen's management team includes the folowing people:
- Mr. Mark J. Enyedy, Pres, CEO, Interim Principal Financial Officer & Director (Age 55)
- Dr. Richard J. Gregory, Exec. VP & Chief Scientific Officer (Age 61)
- Mr. Craig Barrows, Exec. VP, Gen. Counsel & Sec. (Age 64)
- Dr. Anna Berkenblit, VP & Chief Medical Officer (Age 49)
- Mr. David Foster, VP of Fin. & Chief Accounting Officer
Who are ImmunoGen's major shareholders?
ImmunoGen's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.30%), Northern Trust Corp (1.19%), Geode Capital Management LLC (1.15%), Two Sigma Investments LP (0.74%), Jennison Associates LLC (0.72%) and Candriam Luxembourg S.C.A. (0.68%). Company insiders that own ImmunoGen stock include Anna Berkenblit, Craig Barrows, Daniel M Junius, David Brannon Johnston, Mark Alan Goldberg, Mark J Enyedy and Richard J Gregory. View Institutional Ownership Trends for ImmunoGen.
Which institutional investors are selling ImmunoGen stock?
IMGN stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Raymond James & Associates, MetLife Investment Advisors LLC, Pinnacle Associates Ltd., Bank of America Corp DE, Northern Trust Corp, Bank of New York Mellon Corp and Janney Montgomery Scott LLC. Company insiders that have sold ImmunoGen company stock in the last year include Anna Berkenblit, Daniel M Junius, David Brannon Johnston and Richard J Gregory. View Insider Buying and Selling for ImmunoGen.
Which institutional investors are buying ImmunoGen stock?
IMGN stock was bought by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Opaleye Management Inc., BlackRock Inc., Sofinnova Investments Inc., California Public Employees Retirement System, Squarepoint Ops LLC, Sectoral Asset Management Inc and Two Sigma Advisers LP. View Insider Buying and Selling for ImmunoGen.
How do I buy shares of ImmunoGen?
Shares of IMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ImmunoGen's stock price today?
One share of IMGN stock can currently be purchased for approximately $5.73.
How big of a company is ImmunoGen?
ImmunoGen has a market capitalization of $854.29 million and generates $53.82 million in revenue each year. The biotechnology company earns $-167,870,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis. ImmunoGen employs 293 workers across the globe.
What is ImmunoGen's official website?
How can I contact ImmunoGen?
ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 781-895-0600 or via email at [email protected]
MarketBeat Community Rating for ImmunoGen (NASDAQ IMGN)
MarketBeat's community ratings are surveys of what our community members think about ImmunoGen and other stocks. Vote "Outperform" if you believe IMGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
